AnaptysBio, Inc. (ANABV)San Diego, United States | NasdaqGS
43.80 USD
+0.80
(1.860%)
⇧
(April 17, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:57 a.m. EDT
AnaptysBio exhibits a growth-at-a-reasonable-price dilemma with explosive revenue trajectory (151% growth) offset by severe dilutive debt-to-equity (781%) and negative long-term valuation metrics; the stock is currently neutral on technicals (tight range below 50 SMA) with no dividend income or short-term catalysts driving momentum. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 781.08 |
| Revenue per Share | 8.158 |
| Beta | 0.41 |
| Profit Margins | -5.64% |
| Website | https://www.anaptysbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03778559 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 210 |
| All Time High | 49.76 |
| All Time Low | 41.99 |
| Ask | 46.96 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 2,110 |
| Average Daily Volume3 Month | 2,110 |
| Average Volume | 2,110 |
| Average Volume10Days | 2,110 |
| Beta | 0.406 |
| Bid | 39.51 |
| Bid Size | 1 |
| Book Value | 1.328 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 43.8 |
| Current Ratio | 9.068 |
| Custom Price Alert Confidence | HIGH |
| Day High | 43.8 |
| Day Low | 42.0 |
| Debt To Equity | 781.08 |
| Display Name | AnaptysBio |
| Ebitda | 48,455,000 |
| Ebitda Margins | 0.20653999 |
| Enterprise To Ebitda | 25.553 |
| Enterprise To Revenue | 5.278 |
| Enterprise Value | 1,238,175,616 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 44.844 |
| Fifty Day Average Change | -1.0440025 |
| Fifty Day Average Change Percent | -0.023280762 |
| Fifty Two Week Change Percent | -3.778559 |
| Fifty Two Week High | 49.76 |
| Fifty Two Week High Change | -5.959999 |
| Fifty Two Week High Change Percent | -0.11977491 |
| Fifty Two Week Low | 41.99 |
| Fifty Two Week Low Change | 1.8099976 |
| Fifty Two Week Low Change Percent | 0.043105442 |
| Fifty Two Week Range | 41.99 - 49.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,775,482,200,000 |
| Float Shares | 17,263,040 |
| Free Cashflow | 19,342,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 104 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.42043 |
| Gross Profits | 98,633,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,026-04-06 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. |
| Long Name | AnaptysBio, Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28462113 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,232,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 42.04 |
| Operating Cashflow | 19,697,000 |
| Operating Margins | 0.61803 |
| Phone | 858 362 6295 |
| Previous Close | 43.0 |
| Price Hint | 2 |
| Price To Book | 32.98193 |
| Profit Margins | -0.056399997 |
| Quick Ratio | 8.945 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.79999924 |
| Regular Market Change Percent | 1.8604634 |
| Regular Market Day High | 43.8 |
| Regular Market Day Low | 42.0 |
| Regular Market Day Range | 42.0 - 43.8 |
| Regular Market Open | 42.04 |
| Regular Market Previous Close | 43.0 |
| Regular Market Price | 43.8 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,209 |
| Return On Assets | 0.07058 |
| Return On Equity | -0.24486 |
| Revenue Growth | 1.511 |
| Revenue Per Share | 8.158 |
| Sand P52 Week Change | 0.38150132 |
| Sector | |
| Sector Key | |
| Short Name | AnaptysBio, Inc. Common Stock When Issued |
| Source Interval | 15 |
| State | CA |
| Symbol | ANABV |
| Total Cash | 311,638,016 |
| Total Cash Per Share | 10.84 |
| Total Debt | 290,640,000 |
| Total Revenue | 234,603,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 44.844 |
| Two Hundred Day Average Change | -1.0440025 |
| Two Hundred Day Average Change Percent | -0.023280762 |
| Type Disp | Equity |
| Volume | 2,209 |
| Website | https://www.anaptysbio.com |
| Zip | 92,121-5801 |